Category: news
Northwoods NETS is pleased to announce that we have a very special meeting set up for September! This will take the place of our usual in-person support meeting in September. We are coordinating with the the professional group called North American…
We have a very special meeting set up for September! We are coordinating with the North American Neuroendocrine Tumor Society (NANETS) and Learn Advocate & Connect—A Neuroendocrine Tumor Society (LACNETS) to have a Regional NET Patient Education Conference on Saturday,…
University of Iowa Holden Comprehensive Cancer Center is the first U.S. cancer center to be designated a Neuroendocrine Tumor Center of Excellence by the European Neuroendocrine Tumor Society (ENETS). In making the award to the Iowa team in early March, ENETS…
Northwoods NETS is pleased to announce that Senator Mark Dayton has proclaimed Friday, November 10th, NET Cancer Awareness Day in the state of Minnesota. We thank Governor Dayton for his continued recognition of this unusual cancer. It is estimated that…
The National Comprehensive Cancer Network (NCCN) has recently released a new guideline book for patients diagnosed with neuroendocrine tumors. With very readable language it discusses what neuroendocrine tumors are, how they are diagnosed, the various types of treatments that are…
After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients…
Advanced Accelerator Applications S.A. (AAA) has announced that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera). Lutathera…
A new paper has recently been released in Digestion: International Journal of Gastroenterology that reviewed previously reported European trials. These trials specifically aimed at the treatment of advanced pancreatic neuroendocrine tumors outlined several combinations of chemotherapy drugs used to help with…
We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded…
It’s not often that we have a reason to discuss reality television shows here on Northwoods NETS, but, we have a notable exception right now. The Voice contestant, Felicia Temple, 28, is also a neuroendocrine tumor patient. An amazing vocalist and…
